Tc Biopharm Holdings Stock Analysis

TCBP Stock Analysis Notes

The company has price-to-book ratio of 1.16. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. TC BioPharm Holdings recorded a loss per share of 192.95. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 5th of August 2024. TC Biopharm Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Tc Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. To find out more about TC BioPharm Holdings contact Bryan Kobel at 44 14 1433 7557 or learn more at https://tcbiopharm.com.

TC BioPharm Holdings Investment Alerts

TC BioPharm Holdings Upcoming and Recent Events

TCBP Stock Institutional Investors

Note, although TC BioPharm's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

TCBP Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 360.37 K.

TCBP Profitablity

Management Efficiency

TC BioPharm Holdings has return on total asset (ROA) of (1.0892) % which means that it has lost $1.0892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.1748) %, meaning that it created substantial loss on money invested by shareholders. TC BioPharm's management efficiency ratios could be used to measure how well TC BioPharm manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/01/2025, Return On Tangible Assets is likely to drop to -0.67. In addition to that, Return On Capital Employed is likely to drop to -4.11. As of 02/01/2025, Total Current Liabilities is likely to grow to about 9.4 M, while Liabilities And Stockholders Equity is likely to drop slightly above 10 M.

Technical Drivers

As of the 1st of February, TC BioPharm owns the information ratio of (0.27), and Market Risk Adjusted Performance of (1.59). In connection with fundamental indicators, the technical analysis model makes it possible for you to check timely technical drivers of TC BioPharm Holdings, as well as the relationship between them.

TC BioPharm Holdings Price Movement Analysis

TC BioPharm Holdings Insider Trading Activities

TC BioPharm Outstanding Bonds

TC BioPharm Predictive Daily Indicators

TC BioPharm Forecast Models

TC BioPharm's time-series forecasting models are one of many TC BioPharm's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary TC BioPharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how TC BioPharm prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling TCBP shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as TC BioPharm. By using and applying TCBP Stock analysis, traders can create a robust methodology for identifying TCBP entry and exit points for their positions.

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.